Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
2.48
USD
|
+1.64%
|
|
-0.80%
|
-0.80%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
116.9
|
160.7
|
200.1
|
38.07
|
20.65
|
33.11
|
-
|
-
|
Enterprise Value (EV)
1 |
97.52
|
156.8
|
200.1
|
38.07
|
20.65
|
33.11
|
33.11
|
33.11
|
P/E ratio
|
-5.11
x
|
-5.2
x
|
-3.01
x
|
-0.49
x
|
-0.67
x
|
-1.04
x
|
-1.25
x
|
-1.04
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
132
x
|
25.9
x
|
6.8
x
|
13.7
x
|
22.8
x
|
5.61
x
|
3.76
x
|
EV / Revenue
|
-
|
132
x
|
25.9
x
|
6.8
x
|
13.7
x
|
22.8
x
|
5.61
x
|
3.76
x
|
EV / EBITDA
|
-5.34
x
|
-5.08
x
|
-5
x
|
-0.75
x
|
-
|
-9.74
x
|
-1.79
x
|
-1.8
x
|
EV / FCF
|
-5,667,563
x
|
-5,907,633
x
|
-5,240,970
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.74
x
|
4.93
x
|
3.07
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,599
|
3,363
|
4,612
|
5,932
|
8,261
|
13,350
|
-
|
-
|
Reference price
2 |
45.00
|
47.80
|
43.40
|
6.418
|
2.500
|
2.480
|
2.480
|
2.480
|
Announcement Date
|
3/25/20
|
3/16/21
|
3/10/22
|
3/31/23
|
4/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1.216
|
7.727
|
5.6
|
1.503
|
1.451
|
5.904
|
8.8
|
EBITDA
1 |
-21.9
|
-31.64
|
-40.03
|
-50.71
|
-
|
-3.4
|
-18.5
|
-18.4
|
EBIT
1 |
-22.24
|
-29.71
|
-74.21
|
-72.29
|
-25.14
|
-21.49
|
-19.6
|
-18.4
|
Operating Margin
|
-
|
-2,443.34%
|
-960.42%
|
-1,290.84%
|
-1,672.39%
|
-1,481.07%
|
-332.01%
|
-209.09%
|
Earnings before Tax (EBT)
1 |
-22.43
|
-31.19
|
-73.36
|
-18.61
|
-24.86
|
-21.42
|
-19.53
|
-18.4
|
Net income
1 |
-22.43
|
-29.93
|
-64.1
|
-72.9
|
-28.72
|
-22.08
|
-20.19
|
-20.4
|
Net margin
|
-
|
-2,461.51%
|
-829.52%
|
-1,301.82%
|
-1,911.04%
|
-1,522.06%
|
-342.08%
|
-231.82%
|
EPS
2 |
-8.800
|
-9.200
|
-14.40
|
-13.20
|
-3.750
|
-2.390
|
-1.977
|
-2.390
|
Free Cash Flow
|
-20.63
|
-27.21
|
-38.19
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-2,237.42%
|
-494.22%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/20
|
3/16/21
|
3/10/22
|
3/31/23
|
4/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.984
|
3.589
|
1.425
|
2.067
|
1.017
|
1.1
|
0.297
|
0.463
|
0.429
|
0.314
|
0.35
|
0.404
|
0.3939
|
0.476
|
0.5916
|
EBITDA
1 |
-11.19
|
-7.018
|
-13.34
|
-9.826
|
-12.95
|
-11.06
|
-8.664
|
-5.438
|
-4.718
|
-
|
-0.9
|
-0.9
|
-0.8
|
-0.8
|
-
|
EBIT
1 |
-13.6
|
-35.68
|
-9.895
|
-8.562
|
-9.221
|
-44.66
|
2.872
|
-8.294
|
-6.513
|
-16.18
|
-5.341
|
-5.368
|
-5.348
|
-5.432
|
-5.362
|
Operating Margin
|
-1,382.52%
|
-994.15%
|
-694.39%
|
-414.22%
|
-906.69%
|
-4,060.36%
|
967%
|
-1,791.36%
|
-1,518.18%
|
-5,152.55%
|
-1,526.12%
|
-1,328.53%
|
-1,357.63%
|
-1,141.32%
|
-906.38%
|
Earnings before Tax (EBT)
1 |
-13.8
|
-35.79
|
-10.29
|
-8.3
|
-9.333
|
9.312
|
5.959
|
-8.333
|
-6.489
|
-13.07
|
-5.307
|
-5.366
|
-5.346
|
-5.397
|
-5.31
|
Net income
1 |
-13.8
|
-35.88
|
-10.29
|
-8.3
|
-9.333
|
-44.98
|
3.033
|
-8.333
|
-6.489
|
-16.2
|
-5.473
|
-5.533
|
-5.513
|
-5.564
|
-5.31
|
Net margin
|
-1,402.44%
|
-999.86%
|
-722.25%
|
-401.55%
|
-917.7%
|
-4,088.91%
|
1,021.21%
|
-1,799.78%
|
-1,512.59%
|
-5,157.64%
|
-1,563.84%
|
-1,369.45%
|
-1,399.6%
|
-1,169.05%
|
-897.59%
|
EPS
2 |
-3.000
|
-7.800
|
-2.200
|
-1.400
|
-1.600
|
-8.000
|
0.4000
|
-1.070
|
-0.8100
|
-2.070
|
-0.6700
|
-0.5967
|
-0.5767
|
-0.5767
|
-0.5533
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
3/10/22
|
5/11/22
|
8/10/22
|
11/10/22
|
3/31/23
|
5/11/23
|
8/10/23
|
11/9/23
|
4/12/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
19.4
|
3.92
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-20.6
|
-27.2
|
-38.2
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-72.7%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-56.3%
|
-67.5%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
39.86
|
44.33
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
12.00
|
9.690
|
14.10
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-7.080
|
-8.060
|
-8.080
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.92
|
1.23
|
2.25
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
100.9%
|
29.08%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/20
|
3/16/21
|
3/10/22
|
3/31/23
|
4/12/24
|
-
|
-
|
-
|
Last Close Price
2.48
USD Average target price
4.062
USD Spread / Average Target +63.81% Consensus |
1st Jan change
|
Capi.
|
---|
| -0.80% | 33.11M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|